Literature DB >> 26415615

Recommendations for managing a suboptimal response to biologics for moderate-to-severe psoriasis: A Belgian perspective.

Michel de la Brassinne1, Pierre-Dominique Ghislain2, Jo L W Lambert3, Julien Lambert4, Siegfried Segaert5, Fabienne Willaert6.   

Abstract

Over the past decade, biologics have become the gold standard in the treatment of moderate-to-severe psoriasis for patients who have failed or who have contraindications to traditional systemic treatments. However, although practical recommendations on how to treat a suboptimal response to biologics exist in other chronic inflammatory diseases, they are only just beginning to emerge for psoriasis. This article aims to formulate recommendations in the case of a suboptimal response of psoriasis to biologics in the Belgian setting. A Belgian taskforce of psoriasis experts was convened to review the results of a literature search and formulate recommendations based on the available evidence and provide expert opinion to address gaps in the evidence. The taskforce has proposed a treatment algorithm for patients with a primary non-response or a secondary loss of response to help address an unmet need. Expert recommendations have been developed to address treatment strategies in case of a primary or secondary suboptimal response to biologics in the treatment of moderate-to-severe psoriasis in Belgium.

Entities:  

Keywords:  Algorithm; biologics; immunogenicity; psoriasis; secondary failure

Mesh:

Substances:

Year:  2015        PMID: 26415615     DOI: 10.3109/09546634.2015.1086476

Source DB:  PubMed          Journal:  J Dermatolog Treat        ISSN: 0954-6634            Impact factor:   3.359


  3 in total

1.  Promising Tools to Facilitate the Implementation of TDM of Biologics in Clinical Practice.

Authors:  Rani Soenen; Christophe Stove; Alessio Capobianco; Hanne De Schutter; Marie Dobbelaere; Tahmina Mahjor; Merel Follens; Jo Lambert; Lynda Grine
Journal:  J Clin Med       Date:  2022-05-26       Impact factor: 4.964

2.  Clinical Consequences of Antibody Formation, Serum Concentrations, and HLA-Cw6 Status in Psoriasis Patients on Ustekinumab.

Authors:  Eline De Keyser; Celine I Busard; Sven Lanssens; Lieve Meuleman; Barbara A Hutten; Antonio Costanzo; Juul M van den Reek; Jeffrey Zweegers; Jo Lambert; Phyllis I Spuls
Journal:  Ther Drug Monit       Date:  2019-10       Impact factor: 3.681

3.  Systemic Management of Psoriasis Patients in Indian Scenario: An Expert Consensus.

Authors:  Murlidhar Rajagopalan; Manas Chatterjee; Abhishek De; Sunil Dogra; Satyaki Ganguly; Bikash Ranjan Kar; Nina Madnani; Shekhar Neema; S G Parasramani; Krina Patel; Sushil Tahiliani
Journal:  Indian Dermatol Online J       Date:  2021-09-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.